Clinical Trial Search

Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006

Primary: Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results — 276 Participants

Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale

Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second

Primary: Expanded Disability Status Score — 6.8 score on a scale

Primary: Change From Baseline Contralesional Corticospinal Excitability — 67.88; -37.23 microVolts

Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318

Primary: Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4 — 2.8; 2.8; -0.4; -0.4 Units on a scale — p=0.777

Primary: Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks — -1.55; -1.00 units on a scale

Primary: Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24 — 40.9; 33.3 Percentage of Patients

Primary: Dynamic Component of Spasticity (Spasticity Angle) — 70; 60; 57.5 degree — p=<0.001

Primary: Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Modified Ashworth Score — 0.33; 0.03 score on a scale

Primary: MS Walking Scale-12 (MSWS-12) — 72.6; 82.2 units on a scale — p=0.84

Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale

Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale

Primary: MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 — -0.93; -1.15; -0.96; -1.02 Unit on a scale — p== 0.017

Primary: Change From Baseline in the Ashworth Scale (AS) Score of Plantar Flexors of the Primary Body Side at Day 29 (Week 4) of the First Injection Cycle (1st IC) — -0.7; -0.66…

Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle — 53; 44; 26; 31 participants

Primary: Physician Assessment of Spasticity

Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140

Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache) — 3 participants

Primary: Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern — -0.9; -0.5 units on a scale — p=<0.001

Primary: Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set — 51; 44 participants

Primary: Change From Baseline in Arm Function Based on Motor Activities Log (MAL-O) — 1.52; 1.79 units on a scale

Primary: Change in Normalized Muscle Volume of the Medial Gastrocnemius and the Distal Compartment of the Semitendinosus — -0.08; 0.00; -0.09; -0.01 ml/kg*m

Primary: Motor Control & Learning — 0.339; 0.359; 0.301 Newton

Primary: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) — -0.23; -0.26 units on a scale — p=0.7152

Primary: Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower Limb — -0.86; -0.97; -0.48 units on a scale — p=0.0029

Primary: Spastic Hypertonia as Measured by the Ashworth Scale — 2.4; 2.33; 2.36 score on a scale